Lista de obras - Maximilian von Eynatten - Dominio Público Uruguay

2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial ⬇️

artículo científico publicado el 28 de junio de 2012

A mechanism converting psychosocial stress into mononuclear cell activation

artículo científico publicado en 2003

A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes

artículo científico publicado en 2017

Acute Effect of Empagliflozin on Fractional Excretion of Sodium and eGFR in Youth With Type 2 Diabetes

scientific article published on 25 June 2018

Adipocytokines as a novel target for the anti-inflammatory effect of atorvastatin in patients with type 2 diabetes

artículo científico publicado en 2005

Adiponectin and prognostic outcome in patients with coronary artery disease: reply

scholarly article by Maximilian von Eynatten et al published 13 May 2008 in European Heart Journal

Altered molecular weight forms of adiponectin in hypertension

artículo científico publicado en 2009

Analysis from the EMPA-REG OUTCOME® trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics

artículo científico publicado en 2019

Association of lipopolysaccharide-binding protein and coronary artery disease in men.

artículo científico publicado en 2007

Associations of fetuin-A levels with vascular disease in type 2 diabetes patients with early diabetic nephropathy.

artículo científico publicado en 2010

Atherogenic dyslipidaemia but not total- and high-molecular weight adiponectin are associated with the prognostic outcome in patients with coronary heart disease

artículo científico publicado en 2008

Blood glucose, diabetes and metabolic control in patients with community-acquired pneumonia

artículo científico publicado en 2020

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme ⬇️

artículo científico publicado el 10 de enero de 2012

Changes in adiponectin multimer distribution in response to atorvastatin treatment in patients with type 2 diabetes

artículo científico publicado en 2009

Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration

artículo científico publicado en 2014

Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose co-transporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial

scientific article published on 09 November 2020

Choice of endpoint in kidney outcome trials: considerations from the EMPA-REG OUTCOME® trial

scientific article published on 08 September 2019

Circulating Adipocyte Fatty Acid-Binding Protein Levels and Cardiovascular Morbidity and Mortality in Patients With Coronary Heart Disease

scholarly article by Maximilian von Eynatten et al published September 2012 in Arteriosclerosis, Thrombosis, and Vascular Biology

Combination of the dipeptidyl peptidase-4 inhibitor linagliptin with insulin-based regimens in type 2 diabetes and chronic kidney disease

artículo científico publicado en 2015

Comparing aortic stiffness in kidney transplant recipients, hemodialysis patients, and patients with chronic renal failure ⬇️

artículo científico publicado el 26 de abril de 2011

Comparison of immunoassays for the selective measurement of human high-molecular weight adiponectin

artículo científico publicado en 2009

Composite Primary End Points in Cardiovascular Outcomes Trials Involving Type 2 Diabetes Patients: Should Unstable Angina Be Included in the Primary End Point?

artículo científico publicado en 2017

Consistent Effects of Empagliflozin on Cardiovascular and Kidney Outcomes Irrespective of Diabetic Kidney Disease Categories - Insights from the EMPA-REG OUTCOME trial

artículo científico publicado en 2020

Decreased plasma lipoprotein lipase in hypoadiponectinemia: an association independent of systemic inflammation and insulin resistance

artículo científico publicado en 2004

Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINA-T2D™ trial

artículo científico publicado en 2015

Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial

artículo científico publicado en 2019

Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial

scientific article published on 01 January 2019

Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial

artículo científico publicado en 2020

Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial

artículo científico publicado en 2017

Efficacy and safety of linagliptin according to patient baseline characteristics: A pooled analysis of three phase 3 trials

artículo científico publicado en 2016

Efficacy and safety of linagliptin in Hispanic/Latino patients with type 2 diabetes mellitus: a pooled analysis from six randomized placebo-controlled phase 3 trials

artículo científico publicado en 2014

Efficacy and safety of linagliptin in subjects with long-standing type 2 diabetes mellitus (>10 years): evidence from pooled data of randomized, double-blind, placebo-controlled, phase III trials

artículo científico publicado en 2014

Efficacy and safety of linagliptin in subjects with type 2 diabetes mellitus and poor glycemic control: pooled analysis of data from three placebo-controlled phase III trials.

artículo científico publicado en 2013

Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trials ⬇️

artículo científico publicado el 9 de abril de 2013

Efficacy and safety of linagliptin to improve glucose control in older people with type 2 diabetes on stable insulin therapy: A randomized trial

artículo científico publicado en 2019

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor linagliptin in black/African American patients with type 2 diabetes: Pooled analysis from eight Phase III trials

artículo científico publicado en 2015

Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial

artículo científico

Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure

artículo científico publicado en 2019

Empagliflozin Induces Transient Diuresis Without Changing Long-Term Overall Fluid Balance in Japanese Patients With Type 2 Diabetes

artículo científico publicado en 2018

Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories: Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Multinational Trial

artículo científico publicado en 2020

Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease

artículo científico publicado en 2017

Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial

artículo científico publicado en 2018

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

artículo científico publicado en 2016

Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: results from the EMPA-REG OUTCOME trial

article

Erratum to: Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration

artículo científico publicado en 2017

Erratum: The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study

scientific article published on 11 February 2019

Fetuin-A and arterial stiffness in patients with normal kidney function

artículo científico publicado en 2008

Fisher-Lewis kidney transplantation model as a tool for investigation of transplantation-induced cardiomyopathy.

artículo científico publicado en 2009

Glucose Control and the Effect of Empagliflozin on Kidney Outcomes in Type 2 Diabetes: An Analysis From the EMPA-REG OUTCOME Trial

artículo científico publicado en 2019

Hemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin with renin-angiotensin system inhibitors in type 2 diabetic patients with albuminuria

scientific article published on 01 June 2019

High-molecular weight adiponectin is independently associated with the extent of coronary artery disease in men.

artículo científico publicado en 2007

Improved glucose control with reduced hypoglycaemic risk when linagliptin is added to basal insulin in elderly patients with type 2 diabetes

artículo científico

Initial combination of linagliptin and metformin compared with linagliptin monotherapy in patients with newly diagnosed type 2 diabetes and marked hyperglycaemia: a randomized, double-blind, active-controlled, parallel group, multinational clinical t

artículo científico publicado en 2014

Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double‐blind, placebo‐controlled study ⬇️

artículo científico publicado el 21 de marzo de 2012

Initial combination of linagliptin and metformin in patients with type 2 diabetes: efficacy and safety in a randomised, double-blind 1-year extension study

artículo científico publicado en 2013

Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes

artículo científico publicado en 2015

Letter to the editor regarding: "Pharmacokinetics of teneligliptin in subjects with renal impairment." Halabi et al., Clinical Pharmacology in Drug Development 2013;2:246-254.

artículo científico publicado en 2014

Levels of three distinct p75 neurotrophin receptor forms found in human plasma are altered in type 2 diabetic patients

scientific article published on 11 May 2007

Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA

artículo científico publicado en 2019

Linagliptin added to sulphonylurea in uncontrolled type 2 diabetes patients with moderate-to-severe renal impairment

artículo científico publicado en 2013

Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA® trial

scientific article published on 22 October 2019

Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial

artículo científico publicado en 2017

Linagliptin for elderly patients with type 2 diabetes - Authors' reply

artículo científico publicado en 2014

Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial ⬇️

artículo científico publicado el 13 de agosto de 2013

Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA1c< 7% with no hypoglycaemia and no weight gain over 2 years ⬇️

artículo científico publicado el 1 de abril de 2013

Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction

scientific article published on 11 September 2013

Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18‐week randomized, double‐blind, placebo‐controlled phase III trial with a 34‐week active‐controlled extension ⬇️

artículo científico publicado el 1 de octubre de 2012

Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study

scientific article published on 17 January 2012

Linagliptin plus metformin in patients with newly diagnosed type 2 diabetes and marked hyperglycemia

artículo científico

Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment.

artículo científico publicado en 2014

Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study

artículo científico publicado en 2012

Long-term safety of linagliptin monotherapy in Japanese patients with type 2 diabetes.

artículo científico publicado en 2012

Low plasma adiponectin levels are associated with increased hepatic lipase activity in vivo

artículo científico publicado en 2005

Low pre-transplant adiponectin multimers are associated with adverse allograft outcomes in kidney transplant recipients a 3-year prospective study

scientific article published on 27 June 2012

MRP8/14 is associated with systemic inflammation in stable coronary atherosclerosis in men.

artículo científico publicado en 2011

No association of the 94T/G polymorphism in the adiponectin gene with diabetic complications

artículo científico publicado en 2005

Non-diabetic chronic kidney disease influences retinal microvasculature

artículo científico publicado en 2009

PPAR gamma variant influences angiographic outcome and 10-year cardiovascular risk in male symptomatic coronary artery disease patients: response to Regieli et al.

artículo científico publicado en 2009

Postprandial mononuclear NF-kappaB activation is independent of the AGE-content of a single meal

artículo científico publicado en 2006

Pulsatile stress correlates with (micro-)albuminuria in renal transplant recipients

artículo científico publicado en 2009

Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high

artículo científico publicado en 2018

Reduction of postprandial hyperglycemia in patients with type 2 diabetes reduces NF-kappaB activation in PBMCs

artículo científico publicado en 2004

Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2-year trial

artículo científico publicado en 2015

Relationship of adiponectin with markers of systemic inflammation, atherogenic dyslipidemia, and heart failure in patients with coronary heart disease

artículo científico publicado en 2006

Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus

artículo científico

Response by Wanner et al to Letters Regarding Article, "Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease"

artículo científico publicado en 2018

Retinol-binding protein 4 & atherosclerosis: risk factor or innocent bystander?

artículo científico publicado en 2009

Retinol-binding protein 4 is associated with components of the metabolic syndrome, but not with insulin resistance, in men with type 2 diabetes or coronary artery disease

artículo científico publicado en 2007

Retinol-binding protein-4 in experimental and clinical metabolic disease

artículo científico publicado en 2008

SDF-1 genotype influences insulin-dependent mobilization of adult progenitor cells in type 2 diabetes

artículo científico publicado en 2005

Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies

artículo científico publicado en 2014

Safety and efficacy of the dipeptidyl peptidase-4 inhibitor linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged ≥ 65 years

artículo científico publicado en 2014

Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus ⬇️

artículo científico publicado el 16 de febrero de 2012

Serum adiponectin levels are an independent predictor of the extent of coronary artery disease in men

artículo científico publicado en 2006

Serum fetuin-A, cardiovascular risk factors, and six-year follow-up outcome in patients with coronary heart disease

artículo científico publicado en 2010

Serum glucose levels for predicting death in patients admitted to hospital for community acquired pneumonia: prospective cohort study

artículo científico publicado en 2012

Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes

artículo científico publicado en 2014

The authors reply

article published in 2020

The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus

scientific article published on 29 January 2014

The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes

artículo científico publicado en 2016

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study

artículo científico publicado en 2018

The proline 12 alanine substitution in the PPARgamma2 gene is associated with increased extent of coronary artery disease in men.

artículo científico publicado en 2009

The role of adiponectin in atherosclerosis: do lipids tip the scales?

artículo científico publicado en 2005

Toll-like receptor polymorphisms and carotid artery intima-media thickness

scientific article published on 17 May 2007

Total and high-molecular weight adiponectin in relation to metabolic variables at baseline and in response to an exercise treatment program: comparative evaluation of three assays: response to Bluher et al.

artículo científico publicado en 2007

Treatment with the dipeptidyl peptidase-4 inhibitor linagliptin or placebo followed by glimepiride in patients with type 2 diabetes with moderate to severe renal impairment: a 52-week, randomized, double-blind clinical trial

artículo científico publicado en 2015

Urinary L-FABP and anaemia: distinct roles of urinary markers in type 2 diabetes

artículo científico publicado en 2009

Urinary Proteomics as a Tool to Identify Kidney Responders to Dipeptidyl Peptidase-4 Inhibition: A Hypothesis-Generating Analysis from the MARLINA-T2D Trial

artículo científico publicado en 2019

Urinary adiponectin excretion: a novel marker for vascular damage in type 2 diabetes

scientific article published on 09 June 2009

Urinary excretion of high molecular weight adiponectin is an independent predictor of decline of renal function in type 2 diabetes

artículo científico publicado en 2013

Urinary n-acetyl-beta-d-glucosaminidase Excretion: an Indicator of Neuropathy in Type 2 Diabetes ⬇️

artículo científico publicado el 20 de septiembre de 2013

[Adipokines and lipid metabolism in type 2 diabetes]

artículo científico publicado en 2007

Lista de obras de Maximilian von Eynatten

2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial ⬇️

A mechanism converting psychosocial stress into mononuclear cell activation

A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes

Acute Effect of Empagliflozin on Fractional Excretion of Sodium and eGFR in Youth With Type 2 Diabetes

Adipocytokines as a novel target for the anti-inflammatory effect of atorvastatin in patients with type 2 diabetes

Adiponectin and prognostic outcome in patients with coronary artery disease: reply

Altered molecular weight forms of adiponectin in hypertension

Analysis from the EMPA-REG OUTCOME® trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics

Association of lipopolysaccharide-binding protein and coronary artery disease in men.

Associations of fetuin-A levels with vascular disease in type 2 diabetes patients with early diabetic nephropathy.

Atherogenic dyslipidaemia but not total- and high-molecular weight adiponectin are associated with the prognostic outcome in patients with coronary heart disease

Blood glucose, diabetes and metabolic control in patients with community-acquired pneumonia

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme ⬇️

Changes in adiponectin multimer distribution in response to atorvastatin treatment in patients with type 2 diabetes

Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration

Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose co-transporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial

Choice of endpoint in kidney outcome trials: considerations from the EMPA-REG OUTCOME® trial

Circulating Adipocyte Fatty Acid-Binding Protein Levels and Cardiovascular Morbidity and Mortality in Patients With Coronary Heart Disease

Combination of the dipeptidyl peptidase-4 inhibitor linagliptin with insulin-based regimens in type 2 diabetes and chronic kidney disease

Comparing aortic stiffness in kidney transplant recipients, hemodialysis patients, and patients with chronic renal failure ⬇️

Comparison of immunoassays for the selective measurement of human high-molecular weight adiponectin

Composite Primary End Points in Cardiovascular Outcomes Trials Involving Type 2 Diabetes Patients: Should Unstable Angina Be Included in the Primary End Point?

Consistent Effects of Empagliflozin on Cardiovascular and Kidney Outcomes Irrespective of Diabetic Kidney Disease Categories - Insights from the EMPA-REG OUTCOME trial

Decreased plasma lipoprotein lipase in hypoadiponectinemia: an association independent of systemic inflammation and insulin resistance

Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINA-T2D™ trial

Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial

Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial

Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial

Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial

Efficacy and safety of linagliptin according to patient baseline characteristics: A pooled analysis of three phase 3 trials

Efficacy and safety of linagliptin in Hispanic/Latino patients with type 2 diabetes mellitus: a pooled analysis from six randomized placebo-controlled phase 3 trials

Efficacy and safety of linagliptin in subjects with long-standing type 2 diabetes mellitus (>10 years): evidence from pooled data of randomized, double-blind, placebo-controlled, phase III trials

Efficacy and safety of linagliptin in subjects with type 2 diabetes mellitus and poor glycemic control: pooled analysis of data from three placebo-controlled phase III trials.

Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trials ⬇️

Efficacy and safety of linagliptin to improve glucose control in older people with type 2 diabetes on stable insulin therapy: A randomized trial

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor linagliptin in black/African American patients with type 2 diabetes: Pooled analysis from eight Phase III trials

Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial

Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure

Empagliflozin Induces Transient Diuresis Without Changing Long-Term Overall Fluid Balance in Japanese Patients With Type 2 Diabetes

Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories: Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Multinational Trial

Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease

Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: results from the EMPA-REG OUTCOME trial

Erratum to: Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration

Erratum: The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study

Fetuin-A and arterial stiffness in patients with normal kidney function

Fisher-Lewis kidney transplantation model as a tool for investigation of transplantation-induced cardiomyopathy.

Glucose Control and the Effect of Empagliflozin on Kidney Outcomes in Type 2 Diabetes: An Analysis From the EMPA-REG OUTCOME Trial

Hemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin with renin-angiotensin system inhibitors in type 2 diabetic patients with albuminuria

High-molecular weight adiponectin is independently associated with the extent of coronary artery disease in men.

Improved glucose control with reduced hypoglycaemic risk when linagliptin is added to basal insulin in elderly patients with type 2 diabetes

Initial combination of linagliptin and metformin compared with linagliptin monotherapy in patients with newly diagnosed type 2 diabetes and marked hyperglycaemia: a randomized, double-blind, active-controlled, parallel group, multinational clinical t

Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double‐blind, placebo‐controlled study ⬇️

Initial combination of linagliptin and metformin in patients with type 2 diabetes: efficacy and safety in a randomised, double-blind 1-year extension study

Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes

Letter to the editor regarding: "Pharmacokinetics of teneligliptin in subjects with renal impairment." Halabi et al., Clinical Pharmacology in Drug Development 2013;2:246-254.

Levels of three distinct p75 neurotrophin receptor forms found in human plasma are altered in type 2 diabetic patients

Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA

Linagliptin added to sulphonylurea in uncontrolled type 2 diabetes patients with moderate-to-severe renal impairment

Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA® trial

Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial

Linagliptin for elderly patients with type 2 diabetes - Authors' reply

Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial ⬇️

Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA1c&lt; 7% with no hypoglycaemia and no weight gain over 2 years ⬇️

Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction

Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18‐week randomized, double‐blind, placebo‐controlled phase III trial with a 34‐week active‐controlled extension ⬇️

Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study

Linagliptin plus metformin in patients with newly diagnosed type 2 diabetes and marked hyperglycemia

Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment.

Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study

Long-term safety of linagliptin monotherapy in Japanese patients with type 2 diabetes.

Low plasma adiponectin levels are associated with increased hepatic lipase activity in vivo

Low pre-transplant adiponectin multimers are associated with adverse allograft outcomes in kidney transplant recipients a 3-year prospective study

MRP8/14 is associated with systemic inflammation in stable coronary atherosclerosis in men.

No association of the 94T/G polymorphism in the adiponectin gene with diabetic complications

Non-diabetic chronic kidney disease influences retinal microvasculature

PPAR gamma variant influences angiographic outcome and 10-year cardiovascular risk in male symptomatic coronary artery disease patients: response to Regieli et al.

Postprandial mononuclear NF-kappaB activation is independent of the AGE-content of a single meal

Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA1c< 7% with no hypoglycaemia and no weight gain over 2 years ⬇️